Regeneron Pharmaceuticals Inc (REGN)
Pretax margin
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | 4,779,900 | 4,969,400 | 4,587,200 | 4,042,000 | 4,199,300 | 4,376,400 | 4,775,400 | 4,655,700 | 4,858,800 | 6,037,500 | 6,344,300 | 9,133,900 | 9,325,800 | 8,047,000 | 7,228,700 | 4,394,800 | 3,810,400 | 3,475,600 | 3,245,800 | 2,551,600 |
| Revenue (ttm) | US$ in thousands | 14,185,900 | 13,812,700 | 13,436,900 | 13,029,000 | 13,044,200 | 13,025,200 | 12,601,200 | 12,306,100 | 12,113,500 | 13,654,100 | 14,171,800 | 16,451,800 | 16,014,400 | 13,499,700 | 12,328,800 | 9,147,000 | 8,455,000 | 8,201,600 | 7,974,500 | 7,957,900 |
| Pretax margin | 33.69% | 35.98% | 34.14% | 31.02% | 32.19% | 33.60% | 37.90% | 37.83% | 40.11% | 44.22% | 44.77% | 55.52% | 58.23% | 59.61% | 58.63% | 48.05% | 45.07% | 42.38% | 40.70% | 32.06% |
December 31, 2024 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $4,779,900K ÷ $14,185,900K
= 33.69%
Regeneron Pharmaceuticals Inc's pretax margin has shown fluctuations over the provided time period. The pretax margin increased steadily from March 2020 to December 2021, reaching its peak at 59.61% in September 2021. However, the pretax margin started to decline from March 2022 onwards, dropping to 31.02% by March 2024. The company experienced a slight recovery in the pretax margin in June 2024 but ended the period at 33.69% in December 2024. Overall, the trend indicates that Regeneron Pharmaceuticals Inc's profitability before taxes has been volatile, with periods of growth followed by declines in the pretax margin.
Peer comparison
Dec 31, 2024